Utilization of smoking-cessation pharmacotherapy among chronic obstructive pulmonary disease (COPD) and lung cancer patients

Abstract

Results showed that a large number of patients continued to smoke even after the diagnosis of COPD and lung cancer; whereas only a few among them used smoking cessation agents. Ethnicity disparities and insurance status were associated with the use of smoking cessation agents. Differential use among population sub-groups suggests a requirement for need based smoking cessation programs and appropriate prescription drug coverage. Further research needs to be done to evaluate reasons for disparities in smoking cessation agents' use. The study had limitations common to research designs based on observational and self-reported datasets.

A Pilot Randomized Controlled Trial of Smoking Cessation in an Outpatient Respirology Clinic

“…Few smoking cessation randomized controlled trials report information regarding the use of pharmacotherapy, making comparison difficult. Previous population-based research suggests that 36% of smokers in Canada used smoking cessation pharmacotherapy in the past six months and that prescription-only medications are not used as frequently as NRT (39,40), which was not found to be the case in our study. It is possible that asking control group participants to set a quit date in the present study may have contributed to an increase in pharmacotherapy use compared with the general population.…”

Final data of an Italian multicentric survey about counseling for smoking cessation in patients with diagnosis of a respiratory disease

“…Unfortunately, this chance is frequently undervalued and many patients continue smoking even after the diagnosis of cancer. 10,15,21 In our study, the vast majority of patients (76%) stopped smoking after the diagnosis, probably due to current physical issues or to the fear of future consequences of smoking on the general health status.…”

“…15,16 Based on these considerations, we performed a prospective cross-sectional study with the aim to investigate if current or former smokers had ever received any kind of information by healthcare professionals about smoking cessation before or after diagnosis of a respiratory disease, including thoracic malignancies. 15,16 Based on these considerations, we performed a prospective cross-sectional study with the aim to investigate if current or former smokers had ever received any kind of information by healthcare professionals about smoking cessation before or after diagnosis of a respiratory disease, including thoracic malignancies.…”

“…In response to the general sensation of the lack of adequate counseling for smoking cessation in Europe, and the evidence of few referral centres in most European countries, multiple studies have shown that many patients actually try to give up smoking, but they generally make their attempts without help, not receiving enough support from physicians. 15,16 Based on these considerations, we performed a prospective cross-sectional study with the aim to investigate if current or former smokers had ever received any kind of information by healthcare professionals about smoking cessation before or after diagnosis of a respiratory disease, including thoracic malignancies. The aim of the study was to understand patients' attitude towards smoking cessation, understood as the disposition of smokers to accept a healthcare intervention finalized to smoking cessation, their appreciation towards this intervention and the emotional aspects that could arise in this particular point of the therapeutic journey of smokers with a respiratory disease, in order to better support them in the purpose of quitting to smoke.…”

Medication Nonadherence: The Role of Cost, Community, and Individual Factors

“…An emerging body of research contextualizes medication adherence using the Health Behavior Model (HBM; Andersen ) to explain behaviors (Unni and Farris ; Vaidya et al. ; Thorpe et al. ).…”